
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas Inc demonstrates a strong positive outlook primarily due to its increasing enterprise value, which has risen from $627 million to $959 million, reflecting heightened market confidence in its innovative pipeline. The valuations of key drug candidates, including ARV-102, ARV-806, and ARV-393, have significantly increased, indicating a positive progression in their development phases and potential commercial success. Additionally, the favorable safety profiles of their protein degradation therapies, evidenced by clinical data such as the 7% AST increase among patients taking ASP3082, lend further credence to the company's promising future in addressing critical healthcare needs.
Bears say
Arvinas Inc faces a negative outlook due to several concerning financial metrics and clinical developments. The projected revenue for its product candidate vepdegestrant has significantly decreased to $296.9 million by 2035, down from a previous estimate of $641.2 million, suggesting reduced market potential stemming from unfavorable economic conditions and limited penetration in key cancer markets. Additionally, the company's challenges in accessing capital could restrict its operational capabilities, impacting the timeline to achieve profitability and sustainable cash flow generation, further compounded by safety concerns arising from adverse effects in ongoing clinical trials.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares